Two RCTs show an Overall Survival benefit of transplant over chemo alone.
2) Does timing early vs delayed matter?
4 RCTs (including IFM 2009) show similar overall survival regardless of when transplant is done (early vs delayed)
The IFM 2009 results show identical overall survival ~60% at 8 years with early or delayed transplant, even though not everyone who is in the delayed transplant group even gets to a transplant. But there are important caveats.
1) All patients in IFM trial were <65. This strategy wonโt work for many older patients whom we consider for transplant.
2) We have other data that for high risk patients survival is better with early transplant
3) There are insurance and storage issues with delayed transplant
4) In many countries transplant is less expensive than drugs used instead of transplant.
5) Longer PFS with early transplant means get time without any big chemo treatments
6) Early transplant allows us to double dip: In selected patients we can consider second transplant.
So my default preference is early transplant followed by maintenance for most patients with myeloma. But if standard risk patients, age<65 are keen on delaying transplant, I would heed the patients wishes & counsel them that their choice is unlikely to compromise overall survival
In summary, auto transplant is like a very effective drug for myeloma & improves survival. We prefer early transplant for various reasons. But IFM data show that in the VRd era delayed transplant produces identical 8yr survival rates. Patient preference must be taken into account
โข โข โข
Missing some Tweet in this thread? You can try to
force a refresh
I started doing personal hashtags at meetings a few years ago for my own selfish reasons. It has worked out great for me. And Iโm hoping itโs useful for others.
I tweet a lot at ASH and other Hematology/oncology meetings but wonโt add my personal hashtag unless I feel like itโs something very important that I would want to look up in the future.
If you are going to offer screening, I suggest only a one-time year at age 50 and older, or 10 years before diagnosis in first degree relative.
Test: SPEP, Serum IFE, and Serum FLC. We are not screening for MGUS, but for evidence suggestive of high risk SMM or MM.
This recommendation affects a small number of people who are at high risk of developing SMM or MM. For all others, including general population, wait till results of iSTOP MM RCT, and other studies such as PROMISE. @sykristinsson@IreneGhobrial
With the pandemic affecting the whole world, we need all the vaccines we can get. Iโm very pleased with the efficacy. I wouldnโt worry about 70% versus 95%. Efficacy is efficacy. @singersrinivas@ShirleySetia
#4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA locus at 16p. Important work. #ASH20#ASH20VR@DanaFarber@NoopurRajeMD
Whether it is masks or meds consider ๐ฌ๐๐๐ฉ ๐๐ ๐ฌ๐ ๐๐ง๐ ๐ง๐๐๐๐ฉ, as well as๐ฌ๐๐๐ฉ ๐๐ ๐ฌ๐ ๐๐ง๐ ๐ฌ๐ง๐ค๐ฃ๐
For benign interventions (eg., masks for COVID) if we say masks work & they donโt, consequence is small. If we say they donโt when they truly do, itโs tragic
For any intervention we have to always consider the consequences of a Type I error relative to the consequences of a Type 2 error.
For many medicines, the consequences of a Type 1 error in terms of toxicity, harm, & cost usually outweighs those of a Type II error. We need RCTs.
Sometimes there are interventions where consequences of erroneously concluding something is effective when it is not (Type I error) is small compared to concluding itโs not effective when it actually is (Type II error). Eg., hand washing to prevent COVID. Masks are like that.
Iโm happy that we rapidly found stuff that works:
-Masks
-Proning
-Dexamethasone
-Monoclonal antibodies
-Upcoming vaccine
Iโm disappointed about the many mistakes:
-Lack of a comprehensive strategy
-Mixed messages
-Politicization of masks
-PPE shortage
As a result of our success we have lowered the number of deaths. But the daily death toll is unacceptably high: ~1000 per day. How can we possibly lower it when the number of new cases is skyrocketing?
If you compare to Europe, you could come to the conclusion that nothing matters. Itโs just the way COVID is. But we have to ask, have they made the same mistakes as us?